药物耐药性和瘤免疫微环境:当前理解的概述 (评论)
Yan Liu1, Jun Liang2, Yanping Zhang2
1Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China.
International journal of oncology
|September 2, 2024
概括
抗癌药物耐药性是一个重大挑战. 本综述探讨了瘤免疫微环境 (TME) 如何影响耐药性,为改善癌症治疗提供了新的治疗点.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
背景情况:
- 抗瘤药物对于癌症治疗至关重要,但耐药性导致转移和复发.
- 瘤免疫微环境 (TME) 包括免疫细胞,细胞因子和免疫调节剂,影响治疗反应.
- 虽然表观遗传变化和药物排放有助于耐药性,但TME的作用越来越被认可.
研究的目的:
- 审查抑制TME有助于抗癌药物耐药性的机制.
- 检查TME内的免疫和代谢变化如何影响免疫监测并促进抵抗.
- 为新的癌症治疗策略确定潜在的基于TME的治疗点.
主要方法:
- 文献综述侧重于TME与药物耐药性之间的相互作用.
- 对研究免疫细胞,细胞因子,肌体细胞和TME中的细胞外基质的研究进行分析.
- 综合证据关于免疫和代谢变化驱动耐药性的证据.
主要成果:
- 通过其组件的协调行动,TME适应促进耐药性.
- 在TME内的免疫和代谢重编程可能会损害抗瘤免疫力.
- 这些TME介导的变化创造了一个有利于瘤生长和治疗失败的环境.
结论:
- TME在癌症耐药性的发展和进展中发挥着重要作用.
- 针对TME的组件为克服阻力提供了有希望的途径.
- 开发调节TME的个性化疗法可以提高癌症治疗效率.
相关概念视频
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
Cytotoxic T Cells-mediated Immune Response
861
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
861
Cell-mediated Immune Responses
67.9K
Overview
67.9K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K


